Lymphocyte-suppressing, endothelial-protective and systemic anti-inflammatory effects of metformin in fenofibrate-treated patients with impaired glucose tolerance

Pharmacological Reports

Volumn 65, Issue 2, 2013, Pages 429-434

  Krysiak, Robert ^a   Gdula Dymek, Anna ^a   Okopien, Boguslaw ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Fibrates; Inflammatory cells; Low grade inflammation; Metformin; Prediabetes

Indexed keywords

C REACTIVE PROTEIN; FATTY ACID; FENOFIBRATE; GAMMA INTERFERON; GLUCOSE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; METFORMIN; PLACEBO; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANOREXIA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG WITHDRAWAL; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; HUMAN CELL; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84879332733     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(13)71018-1     Document Type: Article

References (16)

1. Chinetti-Gbaguidi G, Staels B: Measuring biomarkers to assess the therapeutic effects of PPAR agonists? Pharmacogenomics, 2007, 8, 1567-1580.
2. Hansson GK: Inflammatory mechanisms in atherosclerosis. J Thromb Haemost, 2009, 7, Suppl 1, 328-331.
3. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med, 2002, 346, 393-403.
4. Krysiak R, Gdula-Dymek A, Bachowski R, Okopieñ B: Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes. Diabetes Care, 2010, 33, 2266-2270.
5. Krysiak R, Gdula-Dymek A, Okopieñ B: Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia. Am J Cardiol, 2011, 107, 1010-1018.
6. Krysiak R, Okopieñ B: Lymphocyte-suppressing action of angiotensin-converting enzyme inhibitors in coronary artery disease patients with normal blood pressure. Pharmacol Rep, 2011, 63, 1151-1161.
7. Krysiak R, Okopieñ B: Lymphocyte-suppressing effect of simvastatin in mixed dyslipidemic patients but not impaired glucose tolerance patients. Pharmacol Rep, 2011, 63, 95-101.
8. Okopieñ B, Krysiak R, Kowalski J, Madej A, Belowski D, Zieliñski M, Labuzek K, Herman ZS: The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia. Atherosclerosis, 2004, 176, 327-335.
9. Pruski M, Krysiak R, Okopieñ B: Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia. Diabetes Care, 2009, 32, 1421-1424.
10. Ridker PM: Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr Rev, 2007, 65, S253-S259.
11. Robillard R, Fontaine C, Chinetti G, Fruchart JC, Staels B: Fibrates. Handb Exp Pharmacol, 2005, 170, 389-406.
12. Rosenson RS: Fenofibrate: treatment of hyperlipidemia and beyond. Expert Rev Cardiovasc Ther, 2008, 6, 1319-1330.
13. Schroecksnadel K, Frick B, Winkler C, Fuchs D: Crucial role of interferon-gamma and stimulated macrophages in cardiovascular disease. Curr Vasc Pharmacol, 2006, 4, 205-213.
14. Tedgui A, Mallat Z: Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev, 2006, 86, 515-581.
15. Trepels T, Zeiher AM, Fichtlscherer S: The endothelium and inflammation. Endothelium, 2006, 13, 423-429.
16. Weyand CM, Younge BR, Goronzy JJ: T cells in arteritis and atherosclerosis. Curr Opin Lipidol, 2008, 19, 469-477.